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11. INTRODUCTION
Herbal drugs
Natural products from plant, animal and minerals have been the basis of the
treatment of human disease. Today estimate that about 80 % of people in developing
countries still relays on traditional medicine based largely on species of plants and
animals for their primary health care. Herbal medicines are currently in demand and
their popularity is increasing day by day. About 500 plants with medicinal use are
mentioned in ancient literature and around 800 plants have been used in indigenous
systems of medicine. India is a vast repository of medicinal plants that are used in
traditional medical treatments1. Herbal drugs have great growth potential in global
market. The World Health Organization has recognized the importance of traditional
medicine and has created strategies, guidelines and standards for botanical medicines.
There is a great demand for herbal medicines in the developed as well as developing
countries because of their wide biological activities, higher safety margin than the
synthetic drugs and lesser costs. There has been a major increase in their use in the
last few years in the developed countries like Germany, France, European unions and
U.S.A The World Health Organization (WHO) has listed 21,000 plants, which are
used for medicinal purposes around the world. Among these 2500 species are in India,
out of which 150 species are used commercially on a fairly large scale2. The world
market for herbal medicine, including herbal products and raw materials has been
estimated to have an annual growth rate between 5 and 15%. Total global herbal drug
market is estimated as US $62 billion and is expected to grow to US $5 trillion by the
year 20503.
Herbal drugs have been used since ancient times as medicines for treatment of
a range of diseases. Medicinal plants have played a key role in world health. In spite
of the great advances observed in modern medicine in recent decades, plants still
make an important contribution to health care. Medicinal plants are distributed
worldwide, but they are most abundant in tropical countries. Over the past decade,
interest in drugs derived from higher plants, especially the phytotherapeutic ones, has
increased expressively. It is estimated that about 25% of all modern medicines are
directly or indirectly derived from higher plants. Currently, the major pharmaceutical
companies have demonstrated renewed interest in investigating higher plants as
sources for new lead structures and also for the development of standardized
2phytotherapeutic agents with proved efficacy, safety and quality. Herbal medicinal
preparations are normally very popular in developing countries with a long tradition
in the use of medicinal plants and also in some developed countries such as Germany,
France, Italy and the United States where appropriate guidelines for registration of
medicines exist. Phytomedicines are standardized herbal preparations consisting of
complex mixtures of one or more plants which are used in most countries for the
management of various diseases. Usually, the active principles responsible for their
pharmacological action are unknown. One basic characteristic of herbal medicine is
the fact that they normally do not posses an immediate or strong pharmacological
action. For this reason, herbal medicines are not used for emergency treatment. Other
characteristics of herbal medicines are their wide therapeutic use and great acceptance
by the population. In contrast to modern medicines, herbal medicines are frequently
used to treat chronic diseases. Herbal medicines are normally marketed as
standardized preparations in the form of liquid, solid, or viscous preparations.
Compared with well-defined synthetic drugs, herbal medicines exhibit some
marked differences, namely:
 The active principles are frequently unknown.
 Standardization, stability and quality control are feasible but not easy.
 The availability and quality of raw materials are frequently problematic.
 The well-controlled double-blind clinical and toxicological studies to prove
their efficacy and safety are rare.
 The empirical use in folk medicine is a very important characteristic.
 They have a wide range of therapeutic use and are suitable for chronic
treatments.
 The occurrence of undesirable side effects seems to be less frequent with
herbal medicines, but well-controlled randomized clinical trials have revealed
that they also exist.
 They usually cost less than synthetic drugs.
During the past decades, public interest in herbal medicines, has increased
dramatically not only in developing countries but mainly in industrialized countries.
This has increased international trade in herbal medicines enormously and has
attracted most of the pharmaceutical companies, including the multinationals. The
herbal medicine database indicates that the herbal medicine markets in Asia and Japan
3reach $2.3 and 2.1 billion, respectively. The herbal medicine market has grown at an
expressive rate worldwide4. Several important factors have contributed to the growth
of this worldwide herbal market, among which the following may be mentioned:
 Preference of customers for natural therapies.
 Its concern regarding undesirable side effects of modern medicines and
the belief that herbal drugs are free from side effects, since millions of
people all over the world have been using herbal medicines for
thousands of years.
 Its great interest in alternative medicines.
 The preference of populations for preventive medicine due to
increasing population age.
 The belief that herbal medicines might be of effective benefit in the
treatment certain diseases where conventional therapies and medicines
have proven to be inadequate.
 Tendency towards self-medication
 Improvement in quality, proof of efficacy and safety of herbal
medicines.
 High cost of synthetic medicines.
The general idea that herbal medicines are very safe and free from side effects
is false. Plants have hundreds of constituents and some are very toxic such as the most
cytotoxic and anti-cancer plant derived drugs, digitalis, the pyrolizidine alkaloids,
ephedrine, phorbol esters, etc. However, the adverse effects of most herbal drugs are
relatively less frequent when the drugs are used properly compared with synthetic
drugs, but well-controlled clinical trials now confirm that they really exist. Two kinds
of side effects have been reported for herbal medicines. The first, considered to be
intrinsic to herbal drugs themselves, is mainly related to predictable toxicity, over-
dosage and interaction with urea; drugs, as reported in herbal medicines. Thus many
causes of allergic reactions have been reported for herbal medicines. On the other
hands most of side effects reported for herbal drugs are extrinsic to the preparation
and are selected to manufacturing problems such as misidentification of plants, lack
of standardization, failure of good manufacturing practice, contamination, substitution
and adulteration of plants, incorrect preparations and/or dosage, etc. Since 1978, more
than 4000 herbal preparations have been submitted to pharmacovigilance in Germany
4and most herbal drugs have been withdrawn from the market because of toxic effects
and risks for human use.
Standardization of herbs and quality of herbal preparations
Herbal medicines usually contain a range of pharmacologically active compounds; in
some cases it is not known which ingredients are important for the therapeutic effect5.
Many herbalists believe that isolated ingredients have weaker clinical effects than
whole plant extracts, a notion that would obviously require proof in each case. The
multi-ingredient character of herbal medicines can render efficacy testing more
complex than with synthetic drugs. One approach is to view the entire herbal extract
as the active principle. To optimize the reproducibility of such studies, extracts need
to be sufficiently characterized. This is often attempted through standardization
according to a key constituent of the extract.
Plants contain several hundred constituents and some of them are present in very low
concentrations. In spite of the modern chemical analytical procedures available, only
rarely do phytochemical investigations succeed in isolating and characterizing the all
secondary plant metabolites present in plant extract. Apart from this, plant
constituents vary considerably depending on several factors that impair the quality
control of herbal drugs. Quality control and standardization of herbal medicines
involve several steps. However, the source and quality of raw materials play a pivotal
role in guaranteeing the quality and stability of herbal preparations. Other factors such
as the use of fresh plants, temperature, light, exposure, water availability, nutrients,
period and time of collection, method of collecting, drying, packing, storage and
transportation of raw materials, age and part of plant collected, etc., can greatly affect
the quality and consequently the therapeutic value of herbal medicines. Some plant
constituents are heat labile and the plants containing them need to be dried at low
temperature. Also, other active principles are destroyed by enzymatic processes that
continue for long period of time after plant collection. This explains why frequently
the composition of herbal based drugs is quite variable. Thus, proper standardization
and quality control of raw material and the herbal preparations themselves should be
permanently carried out. In cases where active principles are unknown, marker
substance should be established for analytical purposes. However, in most cases these
markers have never been tested to see whether they really account for therapeutic
action reported for the herbal drugs. As pointed out before, apart from these variable
5factors others such as method of extraction and contamination with microorganisms,
heavy metals, pesticides, etc., can also interfere with quality, safety and efficacy of
drugs. For these reasons pharmaceutical companies prefer using cultivated plants
instead of wild-harvested plants because they show similar variation in their
constituents. Furthermore and certainly more relevant, when medicinal plants are
produced by cultivation, the main secondary metabolites can be monitored and this
permits the definition of the best period for harvesting.
The recent advances which occurred in the process of purification, isolation
and structure elucidation of naturally occurring substances have made it possible to
establish appropriate strategies for the analysis of quality and the process of
standardization of herbal preparations in order to maintain as much as possible the
homogeneity of the plant extract. Thin-layer chromatography, gas chromatography,
high performance liquid chromatography, mass spectrometry, infrared-spectrometry,
ultraviolet/visible spectrometry, etc. used alone or in combination, can be successfully
used for standardization and to control the quality of both raw material and the
finished herbal drugs. The growth of the herbal medicine market has attracted much
interest on the part of the pharmaceutical companies, which has in turn stimulated the
appearance of pre-clinical pharmacological studies and of well controlled and
randomized clinical trials to prove their safety and efficacy6.
During the twentieth century, the emphasis gradually shifted from extracting
medicinal compounds, from plants to making these compounds or their analogues
synthetically. Natural products were widely used as templates for structure
optimization programs designed to make perfect new drugs, referred to by industry as
new chemical entities. Despite the current preoccupation with synthetic chemistry as a
vehicle to discover and manufacture drugs, the contribution of plants to disease
treatment and prevention is still enormous. The greatest recent impact of plant-derived
drugs was probably felt in antitumour area, where taxol, vinblastine, vincristine and
camphothecin have dramatically improved the effectiveness of chemotherapy against
some of the deadliest cancers7.
Despite the complexity of herbal products, investigations of their efficacy are feasible
and desirable, particularly vis-a-vis their popularity. Some herbal medicines are
efficacious for certain indications. All herbal medicines are associated with safety
issues which are often complex8-10.
6The most important pharmaceuticals derived from plants directly or precursors are
listed in Table 1.
7Table 1. Some of the economically important pharmaceuticals or their precursor derived from plants.
S.No Name Type Source Therapeutic uses
Alkaloids
1. Atropine, hyoscyamine,
Scopolamine
Tropane alkaloid Solanaceous species Anticholinergic
2. Camptothecin Indole alkaloid Camphotheca acuminate Antineoplastic
3. Capsaicin Phenylalkyl-amine alkaloid Capsicum species Topical analgesic
4. Codeine, morpine Opium alkaloid Papaver somniferum Analgesic, antitussive
5. Cocaine Cocaine alkaloid Erythroxylum coca Local anaesthetic
6. Colchicine Isoquinoline alkaloid Colchicum autumnale Antigout
7. Emetine Isoquinoline alkaloid Cephaelis ipecacuanha Antiamoebic
8. Galanthamine Isoquinoline alkaloid Leucojum aestivum Cholinesterase inhibitor
9. Nicotine Pyrrolidine alkaloid Nicotiana species Smoking cessation therapy
10. Physostigmine Indole alkaloid Physostigma venenosum Cholinergic
11. Pilocarpine Imidazole alkaloid Pilocarrpus jaborandi Cholinergic
12. Quinine Quinoline alkaloid Cinchona species Antimalarial
13. Quinidine Quinoline alkaloid Cinchona species Cardiac depressant
14. Reserpine Indole alkaloid Rauwolfia serpentina Antihypertensive, Psychotropic
15. Tubocurarine Bisbenzyl isoquinoline alkaloid Chondodendron tomentosum, Skeletal muscle relaxant
8Strychnos toxifera
16. Vinblastine, Vincristine
Yohimbine
Bis-indole alkaloid, indole
alkaloid
Catharanthus roseus Antineoplastic,
Aphrodisiac
Terpenes and steroids
17. Artemisnin Sesquiterpine, Lactone Artemisia annua Antimalarial
18. Diosgenin, hecogenin,
Stigmasterol
Steroids Dioscorea species Oral contraceptives and
hormonal drugs
19. Taxol and other taxoids Diterpines Taxus brevifolia Antineoplastic
Glycosides
20. Digoxin, digitoxin Steroidal glycosides Digitalis species Cardiotonic
21. Sennosides A and B Hydroxy-anthracene glycosides Cassia   angustifolia Laxative
Others and mixtures
22. Podophyllotoxin Lignan Podophyllum peltatum Antineoplastic
9Need of plant based drugs
The lack of reproducibility of activity for greater than 40% of plant extracts is
one of the major obstacles in using plants in pharmaceutical discovery, despite the
great diversity of compounds they synthesize. The activities detected in screens often
do not repeat when plants are resampled and re-extracted. Moreover, the biochemical
profiles of plants harvested at different times and locations vary greatly. In addition,
the currently popular high-throughput drug discovery format favors single compounds
over mixtures and is not compatible with complex plant extracts in which valuable
bioactive molecules are obscured by pigments and polyhenols that interfere with
screens. Equally important is the lack of efficient, rapid strategies to isolate and
characterize a natural product from a plant extract. This is roughly equivalent to the
lifetime of a high-throughput screen for a new target and is a prohibitively long time
in an ever-accelerating lead discovery race. The new chemical entity paradigm of the
twentieth century attempts to treat complex diseases with a single golden molecular
bullet. The first flaw in this paradigm appeared relatively recently when problems of
resistance to antimicrobial and anticancer drugs became apparent. The multifactorial
nature of many complex diseases, such as diabetes, heart disease, cancer and
psychiatric disorders is also an important consideration. Most of these diseases cannot
be ascribed to a single genetic or environmental change but arises from a combination
of genetic, environmental or behavioral factors. The future of herbal drugs depends on
two factors: sustaining a favorable regulatory environment and developing
technologies for the efficient discovery, development and manufacture of herbal
drugs. At present majority of herbal drugs under development are derived from
ethnobotanical sources and traditional medicinal uses11.
Role of herbal drugs in diabetes
The increasing worldwide incidence of diabetes mellitus in adults constitutes a
global public health burden. It is predicted that by 2030, India, China and the United
States will have the largest number of people with diabetes12. Diabetes mellitus is
categorized as a metabolic disease characterized by hyperglycemia resulting from
defects in insulin secretion, insulin action, or both. The vast majority of cases of
diabetes fall into two broad categories, Type 1 diabetes and Type 2 diabetes. The
cause Type 1 diabetes is an absolute deficiency of insulin secretion. In type 2
diabetes, the cause is a combination of resistance to insulin action and an inadequate
compensatory insulin-secretory response13. Despite the great interest in the
10
development of new drugs to prevent the burden of complications associated with this
disease and the raised interest in the scientific community to evaluate either raw or
isolated natural products in experimental studies. Nevertheless, natural supplements
are widely used around the world to treat diabetes, but medical research does not
support their effectiveness. In these studies the low methodological quality, small
sample size of tested patients, and limited number of trials deserve caution in the
interpretation of the positive data and require further examination in high-quality
trials. Nowadays, clinical treatment of diabetes targets both insulin deficiency and
resistance and more recently the prevention of pancreatic cell function decline14-18.
Medicinal plants are being looked up for the treatment of diabetes. Many
conventional drugs have been derived from prototypic molecules in medicinal plants.
To date, over 400 traditional plant treatments for diabetes have been reported,
although only a small number of these have received scientific and medical evaluation
to assess their efficacy. The hypoglycemic effect of some herbal extracts has been
confirmed in human and animal models of type II diabetes. The World Health
Organization Expert Committee on diabetes has recommended that traditional
medicinal herbs be further investigated.
Diabetes mellitus is a complex metabolic disorder resulting from either insulin
insufficiency or insulin dysfunction. Type I diabetes (insulin dependent) is caused due
to insulin insufficiency because of lack of functional beta cells. Patients suffering
from this are therefore totally dependent on exogenous source of insulin while
patients suffering from Type II diabetes (insulin independent) are unable to respond to
insulin and can be treated with dietary changes, exercise and medication. Type II
diabetes is the more common form of diabetes constituting 90% of the diabetic
population19. A list of medicinal plants used in diabetes mellitus is given in Table 2.
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Table 2. Medicinal plants used in Diabetes mellitus
S.No Name of the plant Parts used Extracts used
1. Aegle marmelos Leaves
Seeds
Fruits
Ethanol extract
Aqueous extract
Aqueous extract
2. Aloe vera Leaves Ethanol extract
3. Annona squamosa Leaves Aqueous extract
4. Averroha bilimbi Leaves Aqueous extract, Butanol
extract, Ethyl acetate extract
5. Baccharis trimera Leaves Aqueous extract, Butanol
extract, Ethanol extract
6. Bryophyllum
pinnatum
Leaves Aqueous extract
7. Cichorium intybus Whole plant Ethanol extract
8. Chamaemelum nobile Leaves Aqueous extract
9 Egyptian Morus alba Leaves Alcoholic extract
10. Eugenia jambolana Fruit-pulp, seeds Aqueous, Ethanol extract
11. Allium sativum Bulbs Ethanol extract
12. Mangifera indica Stem-bark Aqueous extract
13. Momordica charantia Leaves, Seeds Aqueous extract
14. Piper bettle Leaves Aqueous, Ethanol extract
15. Psidium guajava Leaves Aqueous extract
16. Raphanus sativus Whole plant Aqueous extract
17. Retama raetum Whole plant Aqueous extract
18. Salavia officinalis Leaves Aqueous extract
19. Scoparia dulcis Whole plant Aqueous extract
20. Strobilanthes crispus Leaves Aqueous extract
21. Syzygium cordatum Leaves Aqueous extract
22. Syzygium cumini Leaves, Seeds Aqueous extract, Ethanol
extract, Butanol extract
23. Taxus yunnanensis Woods Aqueous, Ethanol extract
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24. Terminalia chebula Seeds Chloroform extract
25. Terminalia superba Stem bark Methanol extract, Methylene
chloride extract
26. Trema orientalis Stem bark Aqueous extract
27. Tremella mesenterica Fruits Polysaccharides
28. Triticum repens Rhizomes Aqueous extract
29. Viscum album Whole plant Aqueous, Ethanol extract
30. Zizyphus spina-christi Leaves Butanol extract
Metabolic Dearrangements in diabetes
Type I and Type II diabetes frequently co-occur in the same families,
suggesting common genetic susceptibility. Such mixed family history is associated
with an intermediate phenotype of diabetes: insulin resistance and cardiovascular
complications as well as lower C-peptide concentrations in type II diabetic patients20.
The autoimmune nature of type I diabetes   has been intensively investigated, and it
has long been assumed that the pathogenesis of the disease can be explained by an
interplay between genetics and environment. The pathogenesis of type I diabetes is
that, genetically predisposed individual and environmental factors trigger an
autoimmune process (activation of T lymphocytes reactive to islet cell antigens) that
leads to the destruction of islet cells and insulin deficiency.
Type II diabetes, previously known as NIDDM or adult-onset diabetes, is the
most prevalent form of diabetes, accounting for over 90% of all cases of diabetes.
Type II diabetes is characterized by varying degree of insulin resistance and insulin
deficiency. It is thought that earliest defect in the pathogenesis of type II is impaired
insulin action or insulin resistance. Resistance to the action of insulin will result in
impaired insulin mediated glucose uptake in the periphery (by muscle and fat),
incomplete suppression of hepatic glucose output and impaired triglyceride uptake by
fat. To overcome the insulin resistance (and therefore prevent abnormal fuel
metabolism and maintain normal glucose and lipid levels), beta islet cells will
increase the amount of insulin secreted. Therefore two defects are necessary for
development of type II diabetes insulin resistance and insulin deficiency21.
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Type I diabetes (Insulin dependent diabetes mellitus-IDDM)
Type I diabetes is the most severe type of diabetes, requiring daily insulin
injections on a life long basis. The etiology of Type I diabetes is not well understood.
This type of diabetes results from selective destruction of the insulin producing β cells
of the pancreatic islets of Langerhans, a process that is immunologically mediated and
occurs in genetically susceptible individuals. The islet β-cells are destroyed by an
autoimmune response mediated by T lymphocytes (T cells) that react specifically to
one or more β-cell proteins22.
Type II diabetes (Non insulin dependent diabetes mellitus -NIDDM)
Type II is the most common form of diabetes and is characterized by disorders
of insulin action and insulin secretion, either of which may be the predominant
feature11. Type II diabetes mellitus is a group of disorders characterized by
hyperglycaemia and associated with microvascular (i.e., retinal, renal, possibly
neuropathic), macrovascular (i.e., coronary, peripheral vascular) and neuropathic (i.e.,
autonomic, peripheral) complications. Hyperglycaemia is produced by lack of
endogenous insulin, which is either absolute, as in type I diabetes mellitus, or relative,
as in type II diabetes mellitus. Relative insulin deficiency usually occurs because of
resistance to the actions of insulin in muscle, fat, and the liver and an abnormality
results in decreased glucose transport in muscle, elevated hepatic glucose production,
and increased breakdown of fat23. The natural history of Type II diabetes has four
stages. The first stage begins at birth, when glucose homeostasis is normal but
individuals are at risk for Type II diabetes because of genetic polymorphisms
(diabetogenic genes). During stage II, decrease in insulin sensitivity emerges probably
as a result of a genetic predisposition and lifestyle (environmental), which are initially
compensated by an increase in β-cell function, so that glucose tolerance remains
normal. Later on, both the β-cell function and insulin sensitivity deteriorate, so that
when challenged, as during a glucose tolerance test or a standardized meal,
postprandial glucose tolerance becomes abnormal (stage of impaired glucose
tolerance). At this point, β-cell function is clearly abnormal, but sufficient to maintain
normal fasting plasma glucose concentrations. In stage III, as a result of further
deterioration in β-cell function and increased insulin resistance, fasting plasma
glucose can increase due to an increase in basal endogenous glucose production, but
the patient is still asymptomatic. Finally in stage IV, as a result of further deterioration
in β-cell function, both fasting and postprandial blood glucose levels reach clearly
14
diabetic levels and the patient becomes symptomatic24. Pathophysiology of
hyperglycaemia is given in Figure 1:
Figure 1. Pathophysiology of hyperglycaemia
Gestational diabetes
Gestational diabetes (or gestational diabetes mellitus, GDM) is a condition in
which women without previously diagnosed diabetes exhibit high blood glucose
levels during pregnancy. Gestational diabetes is formally defined as "any degree of
glucose intolerance with onset or first recognition during pregnancy". No specific
cause has been identified, but it is believed that the hormones produced during
pregnancy reduce a woman's sensitivity to insulin, resulting in high blood glucose
levels. Gestational diabetes generally has few symptoms and it is most commonly
diagnosed by screening during pregnancy. Diagnostic tests detect high levels of
glucose in blood samples. Babies born to mothers with gestational diabetes are at
increased risk of complications, primarily growth abnormalities and chemical
imbalances such as low blood glucose. Gestational diabetes is a reversible condition
and women who have adequate control of glucose levels can effectively decrease the
associated risks and give birth to healthy babies. Women with gestational diabetes are
at increased risk of developing type II diabetes mellitus after pregnancy, while their
offspring are prone to developing childhood obesity, with type II diabetes later in life.
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Most patients are treated only with diet modification and moderate exercise but
sometimes anti-diabetic drugs, including insulin becomes necessary25.
Management of diabetes
The goals of treatment for diabetes are to reduce and control blood glucose
levels, relieve the symptoms of the disease, and prevent complications. Long-term
control of blood glucose levels can be assessed by measuring the extent to which
glucose is bound to the A1c component of hemoglobin. This glycosylated hemoglobin
value is expressed as a percentage and should be less than 7% in patients with
diabetes. Numerous studies have demonstrated that intensive treatment and careful
control of blood glucose levels can reduce the risk of complications from diabetes.
The successful management of diabetes requires lifestyle changes for the patient (e.g.,
diet, exercise, self-monitoring of blood and possibly urine). All patients with type I
diabetes require insulin injections. Patients with type II diabetes who have multiple
symptoms are severely hyperglycaemic, or have ketosis (increased ketone production
due to the breakdown of fat for energy) also should use insulin injections. Other
patients with type II diabetes may attempt to control their diabetes through diet and
exercise for a 3-month trial period. However, only 10% of patients with type II
diabetes can control their blood glucose levels with diet and exercise alone. Various
oral antidiabetic agents (or insulin) may be used in conjunction with diet and exercise
to control blood glucose levels in these patients.
Insulin
Injections of insulin help cells take in glucose, thereby reducing blood glucose
levels. Insulin is usually given as intermediate-acting insulin or a mixture of an
intermediate-acting insulin plus a short-acting or rapid-acting insulin. Injections
should be administered at least twice daily. Some patients may require three or more
daily insulin injections or continuous subcutaneous infusions with an insulin pump26.
Oral Antidiabetic Agents
Classes of oral antidiabetic agents include sulfonylureas, biguanides, alpha-
glucosidase inhibitors, meglitinides, and thiazolidinediones. Each class has a unique
mechanism of action, pharmacological effects and adverse-effect profile. If
monotherapy with an oral antidiabetic agent (plus diet and exercise) is ineffective in
controlling blood glucose levels, adding a second antidiabetic agent (preferably with a
different mechanism of action) or insulin is recommended. Using two or more oral
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antidiabetic agents with different mechanisms of action may provide an additive
blood glucose-lowering effect and minimize adverse effects. If combination therapy is
not effective, insulin monotherapy is recommended27.
Sulfonylureas
Sulfonylureas are the best-established oral antidiabetic agents and are a rational
choice for initial drug therapy28. They act primarily to increase insulin secretion by
pancreatic beta cells and can cause hypoglycaemia. Weight gain also can occur with
Sulfonylurea   therapy.
Biguanides
Currently, metformin is the only drug in the biguanide class. Metformin
reduces blood glucose concentrations by increasing glucose uptake in the peripheral
muscles and decreasing the amount of glucose produced and released in the liver. The
most common adverse effects from metformin are diarrhea and other gastrointestinal
disorders. Metformin is contraindicated in patients with renal impairment because of
the risk of lactic acidosis, a potentially serious complication.
Alpha-Glucosidase Inhibitors
The alpha-glucosidase inhibitors, acarbose and miglitol inhibit the action of
intestinal enzymes that break down carbohydrates. These oral antidiabetic agents
delay glucose absorption and are particularly useful for patients with postprandial
hyperglycaemia (high blood glucose levels after eating). However, they are not as
effective as sulfonylureas and biguanides in providing long-term control of blood
glucose levels29. Alpha glucosidase inhibitors do not cause hypoglycemia or weight
gain. However, they can cause flatulence, diarrhea, and abdominal cramps30. Flow
chart for management of diabetes is given in Figure 2.
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Figure 2. Flow chart of management of diabetes mellitus
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2. Review of Literature
INSULIN
Insulin was the first protein for which an amino acid sequence was
determined. It consists of two peptide chains, A and B, of 21 and 30 amino acid
residues, respectively. Insulin is the main hormone controlling intermediary
metabolism. Most cells of the body have insulin receptors which bind with insulin in
the circulation. Structure of Insulin monomer is given in Figure 3. Structure of Insulin
hexamer is given in Figure 4. Chained structure of insulin is given in Figure 5.
Fig. 3.  Structure of Insulin monomer
Insulin is synthesized as a precursor in the rough endoplasmic reticulum31.
Preproinsulin is transported to Golgi apparatus where it undergoes proteolytic
cleavage first to proinsulin and then to insulin plus a fragment of uncertain function
called C-peptide. Insulin and C-peptide are stored in granules in β-cells and are
normally cosecreted by exocytosis in equimolar amounts together with smaller and
variable amounts of proinsulin32,33. The main factor controlling the synthesis and
secretion of insulin is the blood glucose concentration. Insulin is the main hormone
controlling intermediary metabolism, having actions on liver, muscle and fat. Its
overall effect is to conserve energy by facilitating the uptake and storage of glucose,
amino acids and fats after a meal. It reduces blood glucose and fall in plasma insulin
level stimulates blood glucose release. Effect of insulin on glucose uptake and
metabolism is given in Figure 6. Insulin binds to its receptor, which in turn starts
many protein activation cascades. These cascades include: translocation of Glut-4
transporter to the plasma membrane and influx of glucose, glycogen synthesis,
glycolysis and fatty acid synthesis.
19
Fig. 4. Structure of Insulin hexamer
Fig. 5. Chained Structure of insulin
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Fig. 6. Effect of insulin on glucose uptake and metabolism.
Effect of insulin on carbohydrate metabolism
Insulin influences glucose metabolism in liver by inhibiting glycogenolysis
(glycogen breakdown) and gluconeogenesis (synthesis of glucose from non-
carbohydrate sources) while stimulating glycogen synthesis34. It also increases
glucose utilization, but overall effect is to increase hepatic glycogen stores. The main
effect of insulin in muscle, is to increase facilitated transport of glucose via a glucose
transporter called Glut-4, and stimulate glycogen synthesis and glycolysis. Insulin
increases glucose uptake by Glut-4 in adipose tissue as well as in muscle, by
enhancing glucose metabolism. One of the main end products of glucose metabolism
in adipose tissue is glycerol, which is esterified with fatty acids to form triglycerides.
Effect of insulin on fat metabolism
Insulin increases fatty acid as well as triglyceride synthesis in adipose tissue
and liver. It inhibits lipolysis, partly via dephosphorylation of lipases. It also inhibits
the lipolytic actions of adrenaline, growth hormone and glucagon by opposing their
action on adenylate cyclase.
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Effect of insulin on protein metabolism
Insulin stimulates uptake of amino acids into muscle and increases protein
synthesis. It also decreases protein catabolism and inhibits oxidation of amino acids in
the liver.
Mechanism of action of insulin
Insulin binds to a specific protein receptor on the surface of its target cells.
The receptor is a large transmembrane glycoprotein complex consisting of two α and
two β-subunits. The α-subunits are entirely extracellular and each carries an insulin-
binding state, where as the β-subunits are transmembrane proteins with tyrosine
kinase activity. This activity is suppressed by the α-subunits, but insulin binding
causes a conformational change that activates the tyrosine kinase activity of the β
subunits which act on each other and on other target proteins. 10 % of receptors are
occupied at maximum concentration of insulin. Occupied receptors aggregate into
clusters, which are subsequently internalized in vesicles, resulting in down regulation.
Internalized insulin is degraded in lyosomes, but the receptors are recycled to the
plasma membrane35. Mechanism of insulin release is given in Figure 7.
Fig. 7. Mechanism of insulin release
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ATP-sensitive potassium channels (‘KATP’) determine the resting membrane
potential in β-cells. Glucose enters β-cells via a membrane transporter called Glut-2,
and its subsequent metabolism via glucokinase and glycolysis increases intracellular
ATP. This blocks KATP , causing membrane depolarization and opening of voltage
dependent calcium channels, leading to Ca2+ influx. The Ca2+ signal induces insulin
secretion, but only in the presence of amplifying messengers including  diacylglycerol
(DAG), non-esterified arachidonic acid (which facilitates further Ca2+ entry ) and 12-
lipoxygenase products of arachidonic acid mainly 12S-hydroxyeicosatetraenoic acid
(12-S-HETE). Phospholipases are commonly activated by Ca2+, but free acrachidonic
acid is liberated in β-cells by an ATP-sensitive Ca2+ insensitive (‘ASCI’)
phospholipase A2.
Consequently, in β-cells Ca2+ entry and arachidonic acid production are both
driven by ATP, linking cellular energy status to insulin secretion. Many
gastrointestinal hormones stimulate insulin secretion, including gastrin, secretin,
cholecystokinin, gastric inhibitory polypeptide (GIP), glucagon-like peptide (GLP)
and GLP1 (the amide of a fragment of GLP). Insulin release is inhibited by the
sympathetic nervous system. Adrenaline increases blood glucose by inhibiting insulin
release and by promoting glycogenolysis via β2–adrenocepters in striated muscle and
liver. Several peptides, including somatostatin, galanin (an endogeneous ATP-
sensitive potassium channel activator) and amylin, also inhibit insulin release.
Mechanism of insulin dependent glucose release is given in Figure 8.
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Fig. 8.  Mechanism of glucose dependent insulin release
Oral medication used in treatment of Diabetes
The following Oral medication used in treatment of diabetes36-41.
Repaglinide
It is a meglitinide that stimulates insulin release by pancreatic beta cells,
although it is not a sulfonylurea. Repaglinide is indicated as monotherapy, but if
blood glucose control cannot be achieved with repaglinide, then given in combination
with metformin. Repaglinide and metformin together act synergistically to reduce
glucose levels to lower levels than can be achieved with either drug alone.
Repaglinide usually is taken two to four times a day, within 30 minutes before meals.
Adverse effects include hypoglycemia and weight gain. Patients who are elderly, or
malnourished or who have adrenal, pituitary, or hepatic insufficiency are particularly
susceptible to hypoglycaemic reactions. Causes of Hyperglycaemia and action of oral
antidiabetic agents is given in Figure 9.
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Fig.  9. Causes of Hyperglycaemia and action of oral antidiabetic agents
Nateglinide
It is a non-sulfonylurea with a mechanism of action   similar to that of
repaglinide; it stimulates the release of insulin by pancreatic beta cells. Like
repaglinide, nateglinide is indicated for use as monotherapy or in combination with
metformin. Nateglinide and metformin have a synergistic blood glucose lowering
effect. Nateglinide is taken three times daily, within 30 minutes before meals.
Hypoglycaemia and weight gain can occur during nateglinide therapy.
Thiazolidinediones
Thiazolidinediones are the newest class of antidiabetic agents. They increase
insulin sensitivity and action in liver, muscle, and fatty tissues. Thiazolidinediones
reduce blood glucose concentrations and improve the lipid profile. These agents do
not stimulate insulin secretion or cause hypoglycaemia. However, they can cause
weight gain. The risk of severe liver toxicity appears to be lower with the newer
thiazolidinediones, rosiglitazone and pioglitazone. Thiazolidines bind to gamma form
of peroxisome proliferator-activated receptors (PPARγ). This stimulates peripheral
adipocytes to increase their uptake of fatty acids, which leads to reduction in the fat
stored in the muscle, liver and visceral fat deposits. The thiazolidinediones also lead
to an increase in secretion of adiponectin and decrease in production of resistin and
tumor necrosis factor.
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Glibenclamide
Glibenclamide is an antidiabetic drug belongs to category of Sulphonylureas
included in WHO Model list of Essential Medicines. The drug works by inhibiting
ATP-Sensitive Potassium channels in Pancreatic Beta Cells. This inhibition causes
cell membrane depolarization, opening of Voltage dependent Calcium Channels thus
triggering an increase in intracellular calcium ions into the beta cell which stimulates
Insulin release.
Chemicals used for inducing diabetes mellitus
The following chemicals are generally used for inducing diabetes42
1 Alloxan
2 Steptozotocin
3. Vacor (N-3- Pyridylmethyl-N –P-nitrophenylurea)
4. Dithizone
5. 8-hydroxyquinolone
6. Cyproheptadine
7. Hexamethyl-melamine
Alloxan (2,4,5,6-pyrimidinetetrone) is an oxygenated pyrimidine derivative. It
is present as alloxan hydrate in aqueous solution. Alloxan is a toxic glucose analogue,
which selectively destroys insulin-producing cells in the pancreas (that is beta cells)
when administered to rodents and many other animal species. This causes an insulin-
dependent diabetes mellitus43-45.
Streptozotocin (STZ) is an antibiotic derived from Streptomyces achromogenes and
structurally is a glucosamine derivative of nitrosourea. Its nitrosourea moiety is
responsible for beta cell toxicity, while deoxyglucose moiety facilitates transport
across cell membrane. It induces chemical diabetes in a wide variety of animal species
through a massive destruction of Beta cells of the islets of langerhans and resulting in
a reduced synthesis and release of Insulin46,47. Structure of Streptozotocin is given in
Figure 10.
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Fig. 10. Structure of streptozotocin
Diabetogenic activity of Streptozotocin
Streptozotocin causes alkylation or breakage of DNA strands and a consequent
increase in activity of Poly-ADP-ribose synthetase, an enzyme depleting
Nicotinamide adenine dinucleotide in Beta cells finally leading to energy deprivation
and death of beta cells is reported. Streptozotocin enters the pancreatic Beta-cell via a
glucose transporter-GLUT2. Streptozotocin is a preferred agent to induce
experimental diabetes since it has some advantages over Alloxan such as, relatively
longer half life (15 min), sustained hyperglycaemia for longer duration and the
development of well characterized diabetic complications with fewer incidences of
ketosis as well as mortality. Furthermore, STZ induces activation of poly adenosine
diphosphate ribosylation, an enzyme depleting Nicotinamide in beta cells and nitric
oxide release. As a result of STZ action, pancreatic Beta-cells are destroyed by
necrosis.
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Plant profile
Coldenia  procumbens
Botanical name: Coldenia procumbens Linn.
Synonym: Tripakshi, Tripunkhi
Coldenia procumbens is a weed growing throughout India in moist places. It is
distributed in sandy places, beaches and dry cultivated ground. It is a hygroscopic
species which prefer black soil, mild moisture in and around lake. It grows mainly in
Tamil Nadu, Andhra Pradesh and Gujarat in India48. A photograph of Coldenia
procumbens is given in Figure 11.
Vernacular names
Hindi:       Tripungkee, tripungki, tripunkhi, tripungki
Sanskrit:   Tripakshee, tripakshi, tripakshi, tripakshi
Tamil:       Serupadi, sirupadi, cheruppadi
Telugu:       Hamapadi, hamsapdu, chepputattaku, hamsa padu, bukkinaku
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Fig. 11. Coldenia procumbens
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Description
Leaves are alternate and petiolate. Branches are procumbent spreading flat on
ground. Flowers were small, white, solitary hidden among leaves. A procumbent
annual herb, stems are up to 40 cm. long, radiating, angular or laterally compressed,
much branched, densely hairy to villous. Leaves are with petiole 1-5 mm. long, on the
first ones up to 40 mm. long and lamina 4-23 x 3-15 mm. (on the first leaves 25-43 x
15-32 mm.) Leaves are usually oblong, sometimes circular, ovate, elliptic or obovate,
with appresed hairs diverging from the nerves and converging to the teeth apex above,
densly glandular- hairy below, apex rounded base assymetrical, cuneate on one side,
obtuse to truncate on other, margins deeply crenate to lobed. Flowers are subsessile.
Calyx is 2.5-3.0 mm. long, a little accrescent in fruit, villous outside and inside, lobes
are ovate-lanceolate, subequal. Corolla is 1.5-2.2 mm long, narrowly conical,
calyptriform, early deciduous, white, glabrous. Stamens inserted from the base of the
corolla tube, anthers are suborbicular to broadly elliptic, filaments as long as the
anthers, glabrous. Ovary is ovate-pyramidal, glandular-pubescent, styles are slightly
united at base, early concealed by the apical ptoturbeances of the fruit. Fruit are 4-5
mm wide, depressed-ovoid, 4-lobed, beaked and with irregular proturbeances,
glandular-hairy, brownish dividing at first into two pairs of nutlets, later into 4 nutlets
with the ventral surface angular.48-50
Chemical constituents
Coldenia procumbens contains carbohydrates, tannins, proteins, steroids and
flavonoids50-52. Powder microscopy and Microchemical tests also revealed the
presence of the some chemical nature in the leaves.53
Ethnobotanical uses
It is used in treatment of fever, headache and rheumatic swellings. Root is
used in the form of decoction for impaired digestion and leucorrhoea.
Biological activities
The plant possesses anti-inflammatory activity, analgesic activity and CNS
depressant activity. The benzene, chloroform, acetone, and ethanol extracts of the
leaves of Coldenia procumbens in the dose of 200mg/kg exhibited analgesic
activity.54,55
The ethanol extract of aerial parts of Coldenia procumbens in the dose of 150
mg/kg, produced significant anti-inflammatory activity in male wistar rats.56 The
30
ethanol extract of whole Coldenia procumbens plants showed depression of the
central nervous system in mice and prolongation of the pentobarbital-induced sleeping
time in rats57.
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3. AIM AND PLAN OF WORK
Diabetes mellitus is a metabolic disorder characterized by hyperglycaemia,
glycosuria, hyperlipemia, negative nitrogen balance and ketonemia. A wide-spread
pathological change is thickening of capillary basement membrane, increase in vessel
wall matrix and cellular proliferation resulting in vascular complications like lumen
narrowing, early atherosclerosis, sclerosis of glomerular capillaries, retinopathy,
neuropathy and peripheral vascular insufficiency. There is significant increase in
blood glucose levels, blood cholesterol levels and blood triglycerides levels. Synthetic
drugs available for the treatment of diabetes results in large number produce adverse
effects after prolonged   duration.
There are many herbal remedies suggested for diabetes and diabetic
complications. Medicinal plants form the main ingredients of the herbal remedies.
Several plants have been screened for blood glucose lowering activities on
experimental animals. Individual plants as well as herbal formulations were reported
as hypoglycaemic and antidiabetic agents. However, very few plants have been
studied in depth for the blood glucose lowering effect and mechanism of action for
development as an antidiabetic agent. The plants such as Allium cepa, Allium sativum,
Syzygium cumini, Momordica charantia, Gymnema sylvestre, Pterocarpus
marsupium, Coccinia indica, Trigonella foenum graceum, Psidium guajava and Aegle
marmelos have attracted more attention of scientists in recent years. Coldenia
procumbens has been used for treatment of diabetes in folklore medicine. About 10-
15 leaves are boiled in cup of water and used for diabetes mellitus.
Very little work has been reported on phytochemical Pharmacological
screening of Coldenia procumbens. Hence, it is therefore decided to investigate the
antidiabetic potential of leaves of Coldenia procumbens.
Qualitative chemical tests are proposed to be carried out in the 90% ethanol
extract, 50% ethanol extract and aqueous extract in order to find out the chemical
constituents.
Antidiabetic studies are proposed to be carried out using rats in three different
models. The models proposed are:
1) Fasting glucose model
2) Oral glucose tolerance test (OGTT) in rats and
32
3) Streptozotocin induced diabetes model in rats.
Blood glucose levels, total cholesterol levels, and triglyceride levels would be
estimated to asses the antidiabetic activity of the selected plant extracts.
Plan of work
The plan of present work will be as follows:
Phase: 1
Collection and authentication of plant material.
Phase: 2
a. Preliminary phytochemical studies.
b. Preparation of extracts
i. Preparation of 50% ethanol extract
ii. Preparation of   90% ethanol extract
iii. Preparation of aqueous extract
c. Qualitative chemical tests
Phase: 3
Antidiabetic evaluation of Coldenia procumbens
a. Fasting glucose model
b. Oral glucose tolerance test (OGTT) in rats
c. Streptozotocin induced diabetic model in rats
Phase: 4
Assessment
a. Estimation of Blood glucose levels
b. Estimation of Total cholesterol levels
c. Estimation of triglyceride levels
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Qualitative chemical studies
Extraction
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Fig.  12.   Schematic representation of plan of work
Oral glucose
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18 hr fasting
glucose   model
STZ
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4. Experimental Work
Chemicals and Solvents
All diagnostic kits were purchased from Bayer Diagnostics India Ltd., Baroda,
Gujarat. Streptozotocin was purchased from Sigma Aldrich Co. India. Assay
procedures were followed as per instructions of the manufacturers. All other
chemicals used in present study were of analytical grade. Blood Glucose levels, Total
Cholesterol levels and Triglycerides levels were measured by using Auto Pak.
Collection and Authentication of Plant materials
The plant, Coldenia procumbens was collected from Virrupalli village of
Coimbatore district, Tamilnadu and authenticated by Prof. P.Jayaraman, Plant
Anatomy Research Centre Pharmacognosy Institute, Chennai, India. Leaves of the
plants were collected; shade dried, powdered and packed in an air tight container.
Extraction
Preparation of extracts
Preparation of 50% ethanol extract
200 gm of the air dried and finely ground plant material was extracted with
50% ethanol by cold maceration in a round bottom flask for 24 hrs. After 24 hrs, it
was filtered through Whatman filter paper and the extract was collected in a round
bottom flask. The process was repeated using marc for another two times and all the
three filtrates were collected and combined. The solvent was removed by distillation
and concentrated in vacuo in a rotary evaporator. The dried extract was placed in a
desiccator and used for further studies. The colour, consistency and the percentage
yield of the extract was recorded in Table 6.
Preparation of   90% ethanol extract
200 gm of the air dried and finely ground plant material was extracted with
90% ethanol by cold maceration in a round bottom flask for 24 hrs. After 24 hrs, it
was filtered through Whatman filter paper and the extract was collected in a round
bottom flask. The process was repeated using marc for another two times and all the
three filtrates were collected and combined. The solvent was removed by distillation
and concentrated in vacuo in a rotary evaporator. The dried extract was placed in a
desiccator and used for further studies. The colour, consistency and the percentage
yield of the extract was recorded in Table 6.
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Preparation of aqueous extract
200 gm of air dried and finely ground plant material was extracted with
distilled water by cold maceration in a round bottom flask for 24 hrs. After 24 hrs, it
was filtered through Whatman filter paper and the extract was collected in a round
bottom flask. This process was repeated using marc for another two times and all the
three filtrates were collected and combined. The solvent was removed by distillation
and concentrated in vacuo in a rotary evaporator. The dried extract was placed in a
desiccator and used for further studies. The colour, consistency and the percentage
yield of the extract was recorded in Table 6.
Qualitative chemical tests
The 50% ethanol extract, 90% ethanol extract and aqueous extract were
subjected to preliminary phytochemical screening for the detection of various
phytoconstituents such as alkaloids, steroids, terpenoids, anthraquinone glycosides,
flavonoids, tannins and phenolic compounds, carbohydrates, proteins and amino acids
and mucilages58-61. The following tests were carried out to identify the various
phytoconstituents present in 50% ethanol extract, 90% ethanol extract and aqueous
extract.
1. Test for Carbohydrates
Molisch’s test: To 2-3 ml of extract, added few drops of 95 % α-napthol
solution in alcohol, shake and added conc. H2SO4 from sides of the test tube. Violet ring
was formed at junction of two layers.
Fehling’s solution test: Mixed 1 ml. Fehling’s A and Fehling’s B solutions,
boiled for one minute. To this equal volume of extracts were added. The heated in
boiling water bath for 5-10 min. First a yellow, then brick red precipitates was
observed.
Benedict’s solution test: Mixed equal volume of Benedict’s reagent and
extract in test tube. Heated in boiling water bath for 5 min. Solution was appeared red.
2. Test for Proteins and amino acids
Biuret test: To 3 ml of aqueous extract added 4% NaOH and few drops of 1%
CuSO4 solution. Violet or pink colour was appeared.
Test with Millon’s reagent: Mixed 3 ml of extract with 5 ml Millon’s
reagent. White precipitates were not formed.
36
Xanthoproteic test: Mixed 3ml of extract with 1ml conc.H2SO4. White
precipitates were formed. Precipitates turned to yellow when heated. Added NH4OH,
orange precipitates were not formed.
Ninhydrin solution test: Heated 3 ml of extract and 3 drops of 5% Ninhydrin
solution in boiling water bath for 10 min. Purple or bluish colour was appeared.
3. Test for Flavonoids
Shinoda’s test: To 2ml of extract added 2ml ethanol, few drops of conc. HCl
and little amount of magnesium turnings. Pink colour was observed.
Lead acetate solution test: To small quantity of extract added lead acetate
solution. Yellow coloured precipitates were formed.
Sodium hydroxide solution test: To small quantity of residue added
increasing amount of Sodium hydroxide solution. Yellow colouration was observed.
4. Test for Tannins and Phenolic compounds
To 2-3 ml alcoholic extract added few drops of   following reagents:
5% Ferric chloride solution: Deep blue-black colour was observed.
Lead acetate solution: White precipitates were formed.
Gelatin solution: White precipitates were formed.
Potassium Dichromate: Red precipitates were formed.
Acetic acid solution: Red coloured solution was formed.
Dilute Iodine solution: Transient red colour was observed.
Dilute Nitric acid: Reddish to yellow colour.
5. Test for Steroids
Liebermann-Burchard Reaction: Mixed 2 ml of extract with chloroform.
To this 1-2 ml of acetic anhydride and 2 drops of Conc. sulphuric acid were added
from sides of test tube. First red, then blue and finally green colour was appeared.
Salkowiski Reaction: To 2 ml of extract added, 2 ml chloroform, and 2ml
Conc Sulphuric acid. Shake well, chloroform layer appeared red and acid layer
showed greenish yellow fluorescence.
6. Test for Anthraquinone glycosides
Borntrager’s test: To 3 ml of extract, added dil. H2SO4. Boiled and filtered.
To the filtrate, equal volume of chloroform was added. Shake well and separated
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chloroform layer. Ammonia was added into organic layer. No red or pink colour was
formed.
7. Test for Alkaloids
Extract was dried and treated with few drops of dilute HCl. Filtered and
subjected the filterate to no of tests.
Test with Dragendorff’s reagent: To 2-3 ml of filtrate was added, few drops
of Dragendorff’s reagent. No orange brown precipitates were formed.
Test with Mayer’s reagent: To 2-3 ml filtrate, added few drops of Mayer’s
reagent, cream coloured precipitates were not formed.
Test with Hager’s reagent: To 2-3 ml filtrate, added few drops of Hager’s
reagent. Yellow colour precipitates were not formed.
Test with Wagner’s reagent: To 2-3 ml filtrate added few drops of Wagner’s
reagent. Reddish brown precipitates were not formed.
8. Test for Triterpenoids
Test with Tin and Thionyl chloride: To 2-3 ml of extract, added 2 ml of Tin
and Thionyl chloride. Pink colour was not observed.
9. Test for Mucilages
Alcoholic precipitation test: Added about 2 ml of extract slowly to alcohol
with constant stirring. Filtered the precipitates and dried in air. Precipitates thus
obtained were examined for the presence of carbohydrates.
The results of qualitative chemical tests are tabulated in Table 7.
Pharmacological Studies
Antidiabetic studies of Coldenia procumbens
Animals
The experimental protocol used in the present study was approved by
Institutional Animal Ethical Committee (IAEC).  Male Wister rats weighing 160-180g
and 3-4 months old were selected for study. These rats were kept in 12h-12h
dark/light cycle, temperature of 22 ± 2 ˚C, humidity of 50-60% maintained at Animal
House. During the whole experimental period, animals were fed with a balanced
commercial pellet diet. The animals before experiment were fed with water ad
libitum.
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Biochemical parameters
A number of factors had influenced the outcome of biochemical observations
and control of these factors was important in assessment of the significance of any
changes that were encountered. In particular regularity and accuracy of dosing, the
close control of conditions in animal house, and the control of inter current disease all
bear on the significance of biochemical results and need constant care.
Glucose Estimation
Glucose tests were performed for the diagnosis of diabetes mellitus. In
diabetes mellitus, high blood glucose levels up to 500 mg/dl or more were
encountered, depending on the severity of condition. Except in diabetes mellitus
fasting glucose levels rarely exceeds 110 mg/dl. The collected serum samples of
different study groups were subjected to serum glucose level estimation by enzymatic
GOD-POD method by using glucose diagnostic kit.
Principle of GOD-POD Method
Glucose is oxidized by glucose oxidase into gluconic acid and hydrogen
peroxide. Hydrogen peroxide in presence of peroxidase (POD) oxidizes the
chromogen 4-aminoantipyridine / phenolic compound to a red coloured compound.
The intensity of red coloured compound is proportional to the glucose concentration
and was measured at 505nm.62-64 The final colour is stable for 2 hours.
Glucose +O2 GOD Gluconic Acid + H2O2
H2O2+ Phenolic Compound + 4-Amino-antipyrine POD Red Compound + 2H2O
Reagents
Reagent 1: (Buffer/Enzymes/Chromogen)
Phosphate Buffer                         95 mmol/L
4-aminoantipyrine 0.2 mmol/L
p- hydroxy Benzoic acid             5.9 mmol/L
Glucose Oxidase                          >5000 U/L
Peroxidase                                   >50000  U/L
Standard Glucose (100 mg/dl)
Glucose 1 g/l
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Reagent Reconstitution
One tablet was gently dissolved in 20 ml of distilled water in a clean beaker
with continuous stirring. The solution was then transferred into a dark bottle and
labeled "Working   solution”.
Procedure
The samples and the reconstituting reagent had brought to room temperature
prior to use. The following general parameters were used and reagents prepared   were
given in Table 3.
General system parameters
Reaction type           : End point
Reaction Slope         : Increasing
Wavelength              : 505 nm
Flowcell Temp         :  30ºC
Incubation                : 15 min at 37 ºC or 30 min at room temperature.
Sample Volume : 10 μl
Reagent   Volume : 1 ml
Stdandard concentration: 100mg/dl
Zero setting with    : Reagent Blank
The samples were incubated for 15 min at 37 ºC. Mixed and read.
Table 3. Reagents prepared for measuring glucose levels
Reagents used Blank Standard Test
Working
Solution
1ml 1ml 1ml
Standard - 10 ml -
Sample - - 10 μl
Total Cholesterol Estimation
The determination of serum cholesterol levels is considered to be significant in
coronary artery disease, diabetes mellitus and various other diseases. The
determination of serum cholesterol concentration is one of the most widely performed
assays in biochemistry. Elevated serum cholesterol is supposed to be a risk factor in
the development of arteriosclerosis and myocardial infarction. Cholesterol in blood is
predominantly esterified with fatty acids and associated with lipoproteins. Total
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cholesterol, i.e. the sum of free and esterified cholesterol, can be accurately and
conveniently measured enzymatically using cholesterol oxidase and cholesterol
esterase. Cholesterol esterase which has a broad specificity towards the various fatty
acid residues is used to cleave cholesterol esters to free cholesterol. Subsequently,
Cholesterol oxidase transforms the steroid alcohol into cholest-4-ene-3-one
andhydrogen peroxide which can be quantitated by a spectrophotometric assay e.g.
the oxidative coupling of 4-aminoantipyrine and phenol in the presence of peroxidase
to form a chromogen65-67.
Principle
Cholesterol Ester + H2O2 cholesterol esterase Cholesterol + Fatty Acids
Cholesterol + O2
cholesterol oxidase Cholestenone + H2O2
2H2O2 + Phenol + 4- Aminoantipyrine peroxidase Red quinone + 4H202
The concentration of cholesterol in the sample was directly proportional to the
intensity of the red complex which was measured at 500 nm
.
One of the major uses of cholesterol was the synthesis of bile acids. These
were synthesized in the liver from cholesterol and are secreted in the bile. They were
essential for the absorption of fat from the contents of the intestine.
Reagents
Reagent 1 (Enzymes/chromogen)
Cholesterol Esterase > 200 U/L
Cholesterol Oxidase                       > 250 U/L
Peroxidase                                      >1000 U/L
4-amino antipyrine                          0.5 mmol/L
Reagent 1 A (Buffer)
Pipes buffer, pH 6.90                      50mmol/l
Phenol                                             24 mmol/l
Sodium cholate                               0.5 mmol/l
Standard (Cholesterol 200mg/dl)
Procedure
The samples and the reconstituent reagent should be brought to room
temperature prior to use. The following general parameters were used and reagents
prepared given in Table 4.
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General System Parameters
Reaction type          : End point
Reaction Slope        : Increasing
Wavelength             : 500   nm
Flowcell Temp        : 30ºC
Incubation : 5 min at 37 ºC or 15 min at room temperature.
Sample Volume       : 10 μl
Reagent Volume.   : 1 ml
Standard concentration: 200mg/dl
Zero setting with     : Reagent Blank
Set the instrument using above parameters
The samples were incubated for 15 min at 37 ºC. Mixed and read.
Table 4. Reagents prepared for measuring total cholesterol levels
Reagent used Blank Standard Test
Reconstituting Reagent 1 ml 1 ml 1 ml
Standard - 10 μl -
Sample - - 10 μl
Triglycerides
Triglycerides are the chemical form in which most fat exists in food as well as
in the body. They are also present in blood plasma and, in association with
hyperlipoproteinimia, diabetes mellitus etc. Lipase hydrolyses triglycerides
sequentially to di & monoglycerides and finally to glycerol. Glycerol Kinase (GK)
using ATP as PO4 source converts Glycerol liberated to Glycerol-3-Phosphate (G-3-
Phosphate). G-3-Phosphate Oxidase (GPO) oxidises G-3-Phosphate & forms
dihydroxy acetone phosphate and hydrogen peroxide. Peroxidase (POD) uses the
hydrogen peroxide formed, to oxidise 4-Aminoantipyrine and TOOS (N-ethyl-N-
sulphohydroxy propyl-m Toluidine) to a purple coloured complex. The absorbance of
the coloured complex is measured at 546 nm (530-570 nm or with yellow filter)
which is proportional to Triglyceride concentration.68,69
Principle
Triglycerides + H2O2 lipoprotein lipase Glycerol + Fatty Acid
Glycerol + ATP Glycerol kinase Glycerol-3-Phospate+ADP
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Glycerol-3 Phospate + O2 GPO Dehydroxyacetone Phospate + H2O2
2H2O2+4 Aminoantipyrine + ADPS
peroxidase Red quinone + 4H2O2
GPO = Glycerol- 3-Phospate Oxidase
ADPS = N-Ethyl N-Sulphopropyl–n-anisidine
The intensity of purple coloured complex formed during the reaction was
directly   proportional to the triglycerides concentration in the sample measured at 546
nm. Triglycerides in plasma were derived from fats eaten in foods or made in the
body from other energy sources like carbohydrates. Calories ingested in a meal and
not used immediately by tissues were converted to triglycerides and transported to fat
cells to be stored. Hormones regulate the release of triglycerides from fat tissue so
that they meet the body's needs for energy between meals.
Reagents (Enzymes/chromogen)
Lipoprotein lipase                         > 1100 U/L
Glycerol kinase                             > 800 U/L
Glycerol 3-Phosphate Oxidase     >5000 U/L
Peroxidase                                     >350 U/L
4-Aminoantipyrine                         0.7 mmol/l
ATP 0.3mmol/l
Reagent 1 A (Buffer)
Pipes buffer,   pH   7.50                  50mmol/l
ADPS                                              1 mmol/l
Magnesium salt                               15 mmol/l
Standard (Triglycerides 200mg/dl)
Glycerol  (Trig. Equivalent)             2 g/l
Procedure
The samples and the reconstituting reagent were brought to room temperature
prior to use. The following general parameters were used and reagents prepared were
given in Table 5.
General System Parameters
Reaction type : End point
Reaction Slope : Increasing
Wavelength               : 546   nm
Flowcell Temp          :  30ºC
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Incubation                 : 5 min at 37 ºC
Sample Volume       :  10 μl
Reagent Volume     : 1 ml
Standard concentration      : 200 mg/dl
Zero setting With       : Reagent Blank
Set the instrument using above parameters
Table 5. Reagents used for measuring Triglycerides levels
Reagents used Blank Standard Test
Reconstituting
Reagent
1 ml 1 ml 1 ml
Standard - 10 μl -
Sample - - 10 μl
Experimental Models
Fasting glucose model
Male Wistar rats weighing 160-180g, 3-4 months old were used for study
and maintained at temperature of 22 ± 2˚C and humidity of 50-60% with water ad
libitum during the whole experimental period in animal house.
Each group consists of 6 animals. Extracts were suspended in 1% w/v gum
acacia and administered orally. Blood glucose levels were estimated at 0 h and 3 h
after test extract administration.
Experimental protocol
Rats were divided into 4 groups of 6 rats in each group as mentioned below:
Group I: Rats were treated with vehicle (vehicle control)
Group II: Rats were treated with 90% ethanol extract (250 mg/kg p.o.)
Group III: Rats were treated with 50% ethanol extract (250 mg/kg p.o.)
Group IV: Rats were treated with aqueous extract (250 mg/kg p.o.).
Oral Glucose Tolerance test
In this test, 90% ethanol extract and 50% ethanol extract at a dose of 250
mg/kg p.o., were used for antidiabetic evaluation. Aqueous extract was not used.
Male Wistar rats weighing 160-180 g and 3 to 4 months old were used for study. The
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animals were maintained at temperature of 22 ± 2˚C and humidity of 50-60% with
water ad libitum during the whole experimental period in animal house.
Each group consists of 6 animals. Extracts were suspended in 1% w/v gum
acacia and administered orally. Glucose Solution was prepared in concentration of
1.5g/10 ml and administered one and half hour after drug administration. Blood
glucose levels were measured at 0 min, 30 min, 60 min and 90 min after glucose
administration.
Experimental protocol
Rats were divided into 4 groups of 6 rats in each group as given below
Group I: Rats were treated with vehicle (control).
Group II: Rats were treated with 90% ethanol extract (250 mg/kg p.o.)
Group III: Rats were treated with 50% ethanol extract (250 mg/kg p.o.)
Group IV: Rats were treated with glibenclamide (0.5 mg/kg p.o.)
Streptozotocin induced diabetes Model
Streptozotocin was used in dose of 45 mg/kg i.p. for the induction of diabetes.
Rats with blood glucose levels more than 250 mg/dl and less than 400 mg/dl were
selected for study. Male Wistar rats weighing 160-180g, 3-4 months old were used for
study and maintained at 22 ± 2˚C and humidity of 50-60% with water ad libitum
during the whole experimental period in animal house.
In this model, 90% ethanol extract and 50% ethanol extract at a dose of
250mg/kg p.o., were used for antidiabetic evaluation. Aqueous extract was not used.
Each group consists of 6 animals. Extracts were suspended in 1%w/v gum acacia and
administered orally daily for 21 days to rats. Blood glucose levels were estimated
before induction of diabetes and 1 week after STZ administration. Rats with blood
glucose levels more than 250 mg/dl but less than 400mg/dl were selected for further
study.
Experimental protocol
Rats were divided into 4 groups of 6 rats in each group as given below
Group I: No treatment was given throughout the protocol (normal control)
Group II: No treatment was given throughout the protocol (STZ control)
Group III: Rats were treated with 90% ethanol extract (250 mg/kg p.o.)
Group IV: Rats were treated with 50% ethanol extract (250 mg/kg p.o.)
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Statistical Analysis
The results were expressed as mean ± S.E.M. The data was analyzed using
one- way analysis of variance (ANOVA) followed by Tukey’s Multiple comparison
test. The P value of less than 0.05 was considered to be statistically significant.
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5. RESULTS AND DISCUSSION
Extraction
Preparation of Extracts
The Aqueous extract prepared was blackish brown powder with a
percentage yield of 12.2%w/w. The 50% ethanol extract prepared was blackish
brown in colour with a percentage yield of 8.4 % w/w and 90% ethanol extract
was blackish brown in colour with % yield of 7.1%w/w. The results are
summarized in Table 6. Aqueous extract showed the highest percentage of yield
and 90% ethanol extract showed lowest percentage of yield among these three
extracts prepared from the leaves of Coldenia procumbens.
Table 6. Colour, consistency and % yield of extracts
S.S.no Extract Colour Consistency % yield (w/w)
1. Aqueous extract
Blackish
brown
Solid mass 12.2%
2.
50% ethanol
extract
Blackish
brown
Solid  mass 8.4 %
3.
90% ethanol
extract
Blackish
brown
Solid  mass 7.1 %
Qualitative chemical tests
The 90% ethanol extract, 50% ethanol extract and aqueous extracts of
Coldenia procumbens were subjected for the phytochemical screening. The
qualitative chemical tests revealed the presence of tannins and phenolic
compounds, flavonoids, carbohydrates, amino acids and steroids in 50% ethanol
extract and 90% ethanol extract. Aqueous extract showed the presence of tannins
and phenolic compounds, flavonoids, carbohydrates, proteins, amino acids and
mucilages. Alkaloids are absent in all the three extracts. Results of the qualitative
chemical test are shown in Table 7.
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Table 7. Qualitative phytochemical analysis
SI. No. Tests Aqueous
extract
90% Ethanol
extract
90% Ethanol
extract
1. Alkaloid - - -
2. Carbohydrates + + +
3. Proteins + - -
4. Amino Acids + + +
5. Steroids and Sterols - + +
6. Anthraquinones - - -
7. Flavonoids + + +
8. Tannins and Phenol compounds + + +
9. Triterpenoids - - -
10. Saponins - - -
11. Fixed oils - - -
12. Gums an Mucilage - - -
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Antidiabetic evaluation of Coldenia  procumbens
Antidiabetic evaluation of Coldenia procumbens had been done by using three
models, fasting glucose model, oral glucose tolerance test and streptozotocin induced
diabetes model. The oral glucose tolerance test (OGTT) is a widely used procedure
that was originally developed to classify carbohydrate tolerance70. However, because
plasma glucose and insulin responses during this test reflect the ability of pancreatic -
cells to secrete insulin and the sensitivity of tissues to insulin the OGTT has also been
often used to evaluate -cell function and insulin resistance.71,72
Diabetes is induced by streptozotocin (STZ), a glucosamine-nitrosourea
compound derived from Streptomyces achromogenes that is used clinically as a
chemotherapeutic agent in the treatment of pancreatic β cell carcinoma. STZ damages
pancreatic β cells, resulting in hypoinsulinemia and hyperglycemia73. STZ can induce
a diabetic state in 2 ways, depending on the dose. The selectivity for β cells is
associated with preferential accumulation of the chemical in β cells after entry
through the GLUT2 glucose transporter receptor: chemical structural similarity with
glucose allows STZ to bind to this receptor. The mode of action has best been
demonstrated in mouse studies. At high doses, typically given singly, STZ targets β
cells by its alkylating property corresponding to that of cytotoxic nitrosourea
compounds74. At low doses, generally given in multiple exposures, STZ elicits an
immune and inflammatory reaction, presumably related with the release of glutamic
acid decarboxylase autoantigens. Under this condition, the destruction of β cells and
induction of the hyperglycemic state is associated with inflammatory infiltrates
including lymphocytes in the pancreatic islets75. STZ has well-known adverse side
effects, which include hepatotoxicity and nephrotoxicity76-78.
Fasting glucose model
Rats in group I (vehicle control) showed glucose level of 96.6 ± 2.89 at 0 hour
and 90.20 ± 2.12 at 3 hours respectively. In group II, the rats administered with 90%
ethanol extract showed glucose level of 94.00 ± 1.09 at 0 hour and 88.20 ± 1.00 at 3
hours respectively. Similarly, in group III and group IV rats administered with 50%
ethanol extract and aqueous extract did not reduce blood glucose level in rats. These
results indicate that all the three extracts at a dose of 250mg/kg do not produce any
hypoglycaemic activity in normal rats. Results are given in Table 8 and Figure 13.
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Table 8. Effect of Coldenia procumbens extracts on blood glucose level in
fasting glucose model
Experimental Groups
Blood glucose level (Mean ± S.E.) (mg/dl)
0 h 3 h
Group I - Vehicle control 96.60 ± 2.89 90.20 ± 2.12
Group II -90% Ethanol Extract
(250 mg/kg)
94.00 ± 1.09 88.20 ± 1.00
Group III -50% Ethanol extract
(250 mg/kg)
90.60 ± 2.39 82.80 ± 0.79
Group IV- Aqueous extract
(250 mg/kg)
92.60 ± 1.21 93.80 ± 1.37
Results were expressed as mean ± S.E.M
Fig. 13. Effect of Coldenia proumbens on blood glucose levels in fasting glucose
model
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Results were expressed as Mean±S.E.M.
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Oral glucose tolerance test (OGTT)
Rats in group I (control group) showed blood glucose levels of  99.2 ± 2.75
at 0 hour, 142.00 ± 9.77 at 30 minutes, 119.80 ± 2.33 at 60 minutes and 107.00 ± 1.89
at 90 minutes. In this control group, there is increase in blood glucose levels at 30, 60
and 90 minutes. Maximum increase in blood glucose levels was observed at 30
minutes after glucose solution administration. In group II, III, and IV the blood
glucose levels were 96.20 ± 2.94, 81.80 ± 3.05 and 2.25 ± 2.95 respectively at 0 hour.
After 30 minutes of glucose solution administration to rats of group II, III and IV, it
showed decrease in blood glucose levels when compared to group I. 90% ethanol
extract treated group (group II) showed reduction in blood glucose levels at 30, 60
and 90 minutes when compared to group I. The rats of group III, that received 50%
ethanol extract at dose of 250 mg/kg also showed the reduction in blood glucose
levels at 30, 60 and 90 minutes. The standard drug (glibenclamide-0.5mg/kg) treated
group of rats showed the reduction of blood glucose level at 60 and 90 minutes. In all
the cases, the extract and standard drug treated animals showed near normal level of
blood glucose at 90 minutes. The 90% ethanol extract treated group showed more
reduction of blood glucose level at 60 minutes whereas 50% ethanol extract treated
group showed significant blood glucose level reduction at 30 minutes. The standard
drug (glibenclamide-0.5mg/kg) reduced blood glucose level significantly at 60
minutes whereas it did not produce any reduction in blood glucose level at 30
minutes. Based on these results, it is evident that extracts at a dose of 250 mg/kg body
weight and standard drug (glibenclamide-0.5mg/kg) showed antihyperglycaemic
activity in oral glucose tolerance test. Results are given in Table 9 and Figure 14.
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Table 9: Effect of Coldenia procumbens extracts on blood glucose level in
Oral glucose tolerance test
Experimental
Groups
Blood glucose level (Mean ± S.E.) (mg/dl)
0 min. 30min.# 60 min.# 90 min.#
Group I –
Control group
99.20±2.75 142.00±9.77 119.80±2.33 107.00±1.89
Group II –
90% Ethanol  extract
(250mg/kg)
96.20±2.94 121.00±2.19a 103.00±1.71a 99.00±1.51a
Group III –
50% Ethanol extract
(250 mg/kg)
81.80±3.05 103.40±2.26a 99.00±2.05a 95.20±1.57a
Group IV-
Glibenclamide
(0.5 mg/kg)
92.80±2.95 137.70±3.64 104.00±4.45a 95.20±6.11a
Results were expressed as mean ± S.E.M. # Timing post glucose administration
‘a’ = p<0.05   compared  to control
Fig 14. Effect of Coldenia procumbens extracts on blood glucose levels in Oral
glucose tolerance rats
Results were expressed as mean ± S.E.M. ‘a’= p<.05 compared to vehicle control
0
20
40
60
80
100
120
140
160
180
0 30 60 90
Minutes
G
lu
c
o
s
e
 l
e
v
e
ls
 (
m
g
/d
l)
 Control   90% ethanol extract  50% ethanol extract Glibenclamide
  a
   a  a       a  a a
aa
52
The glucose tolerance test is the most widely used test in rodents to
determine whether a genetically engineered (e.g., transgenic or knockout) or
dietary-induced mouse is glucose intolerant and diabetic. Variables such as fasting
duration, route, and amount of glucose administration, as well as state of
consciousness, may have a large impact on the measured glucose tolerance in
mice. Fasting duration has a major impact on both the plasma glucose and insulin
levels. The overnight- and 24-h-fasted mice has suppressed basal plasma glucose
and insulin levels79,80.
In epidemiological studies, for example, fasting plasma insulin concentrations
have been used as an index of insulin resistance, and the 30 -min ratio of changes in
plasma insulin and glucose have been used as an index of -cell function81,82.
In the present study, the 90% ethanol extract treated group showed more
reduction of blood glucose level at 60 minutes whereas 50% ethanol extract treated
group showed significant blood glucose level reduction at 30 minutes. The standard
drug glibenclamide reduced blood glucose level significantly at 60 minutes. So it may
be concludes that 50% ethanol extract show better antidiabetic activity than 50%
ethanol extract.
Streptozotocin induced diabetes model
Rats in group I (normal control) showed blood glucose levels of 88.30 ± 3.20,
89.10 ± 4.01, 84.80 ± 5.51, 86.90 ± 4.31 and 85.90 ± 2.90 at 0, 7, 14, 21 and 28 day of
experiment. In this normal control group, no change in blood glucose levels is
observed at 7, 14, 21 and 28 day of experiment. In group II, (Streptozotocin control)
rats showed  blood glucose levels of  338.50 ± 11.73, 349.80 ± 21.90, 342.00 ± 20.27
and 300.10 ± 23.03 at 7, 14, 21 and 28 day of experiment. This group showed
significant increase in blood glucose levels at 7, 14, 21, and 28 day of experiment
compared to group I. Nearly 4 times increase in blood glucose level was observed in
Streptozotocin control animals. Rats in group III, showed blood glucose levels of
333.60 ± 14.02, 233.40 ± 17.30, 246.70 ± 10.35 and 191.95 ± 12.60 at 7, 14, 21 and
28 day of experiment respectively. In this group, significant reduction in blood
glucose levels were observed at 14, 21, and 28 day of experiment when compared to
group II. Rats in group IV showed blood glucose levels of 340.01 ± 10.53, 175.05 ±
14.30, 162.80 ± 7.15, and 146.85 ± 14.18 at 7, 14, 21, and 28 day of experiment
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respectively. In this group, significant reduction in blood levels was observed at 14,
21, and 28 day of experiment when compared to group II.
Extracts treated group of rats showed significant reduction of blood glucose
levels at 14, 21 and 28 day indicating the antidiabetic activity of the extract. When
compared to 90% ethanol extract, higher reduction of blood glucose levels were
observed in 50% ethanol extract treated group at day 14, 21 and 28. Based on these
results, it is evident that both the extracts at a dose of 250 mg/kg body weight showed
antidiabetic activity in streptozotocin induced diabetes model. However, higher
reduction of blood glucose levels was observed in rats treated with 50% ethanol
extract treated group. Results are given in Table 10 and Figure 15.
Table 10: Effect of Coldenia procumbens extracts on blood glucose levels in
streptozotocin induced diabetes model
Experimental
Groups
Blood glucose level (Mean ± S.E.) (mg/dl )
Day 0 Day 7 Day 14 Day 21 Day 28
Group I-
Normal control
88.30
± 3.20
89.10
± 4.01
84.80
± 5.51
86.90
± 4.31
85.90 ±
2.90
Group II-
STZ control
87.60
± 5.96
338.50
± 11.73a
349.80
± 21.90a
342
± 20.27a
300.10
± 23.03a
Group III-
90% Ethanol
Extract
(250 mg/kg)
82.10
± 4.47
333.60
± 14.02
233.40
± 17.30b
246.70
± 10.35b
191.95
± 12.60b
Group IV-
50% Ethanol
extract
(250 mg/kg)
86.90
± 3.32
340.01
± 10.53
175.05
± 14.30b
162.80
± 7.15b
146.85
± 14.18b
Results were expressed as mean ± S.E.M. ‘a’ =  p< 0.05 compared to Normal control
‘b’ =  p< 0.05 compared to STZ control
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Fig 15. Effect of Coldenia procumbens extracts on blood glucose levels in
streptozotocin induced diabetes model
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Results were expressed as Mean ±  S.E.M. ‘a’ =  p< 0.05 compared to Normal ontrol;
‘b’ =  p< 0.05 compared to STZ control
Streptozotocin induced diabetes is a well-documented model of experimental
diabetes. Previous reported literature indicates that the type of diabetes and
characteristics differ with the employed dose of STZ and animal and species used83-86.
Streptozotocin induced diabetes provides a relevant example of endogenous
chronic oxidative stress due to the resulting hyperglycemia. STZ is a pancreatic cell
toxin that induces rapid and irreversible necrosis of cells. Whereas a single
diabetogenic dose of STZ (70-250 mg/kg, body weight) has been demonstrated to
induce complete destruction of cells in most species within 24 hour, multiple sub-
diabetogenic doses of STZ partially damage islets, thereby triggering an inflammatory
process leading to macrophage and subsequent lymphocyte infiltration, which is
followed by the onset of insulin deficiency87.
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Effect of Coldenia procumbens extracts on total cholesterol levels in
streptozotocin induced diabetes model
Rats in group I (normal control) showed total cholesterol levels of 57.07 ±
4.40, 60.11 ± 4.87, 59.98 ± 4.30 at 0, 14 and 28 day of experiment respectively. In
this normal control group, no change in total cholesterol levels were obtained at 14,
and 28 day of experiment. Rats in group II showed total cholesterol levels of 61.09 ±
0.98, 57.75 ± 1.41 and 58.12 ± 4.36 at 0, 14 and 28 days of experiment respectively.
Rats in group III, showed total cholesterol levels of 60.18 ± 4.31, 56.33 ± 0.94 and
59.64 ± 3.57 at 0, 14, and 28 days of experiment respectively. Rats in group IV
showed total cholesterol levels of 62.01 ± 3.80, 50.95 ± 1.41 and 57.29 ± 8.64 at 0, 14
and 28 days of experiment respectively. There was no significant changes in the total
cholesterol levels in all group of rats. Results are given in Table 11 and Figure 16.
Diabetes tends to lower "good" cholesterol levels and raise triglyceride and
"bad" cholesterol levels, which increases the risk for heart disease and stroke. This
common condition is called diabetic dyslipidemia. Diabetic dyslipidemia means lipid
profile is going in the wrong direction. It's a deadly combination that puts patients at
risk for premature coronary heart disease and atherosclerosis — where the arteries
become clogged with accumulated fat and other substances. Studies show a link
between insulin resistance, which is a precursor to type 2 diabetes, and diabetic
dyslipidemia, atherosclerosis and blood vessel disease. These conditions can develop
even before diabetes is diagnosed. Hence, reduction in the cholesterol is always
beneficial. However, the extracts used were not showed any effect on the cholesterol
levels.
b
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Table 11: Effect of Coldenia procumbens extracts on total cholesterol levels
in streptozotocin induced diabetes model
Experimental Groups Total Cholesterol levels (Mean ±S.E.) (mg/dl)
Day 0 Day 14 Day 28
Group I-
Normal control
57.07±4.40 60.11±4.87 59.98±4.30
Group II-
STZ control
61.09±0.98 57.75±1.41 58.12±4.36
Group III-
90% ethanol extract (250 mg/kg)
60.18±4.31 56.33±0.94 59.64±3.57
Group IV-
50% ethanol extract (250 mg/kg)
62.01±3.80 50.95±1.41 57.29±8.64
Results were expressed as Mean ± S.E.M.
Fig  16. Effect of Coldenia procumbens extracts on total cholesterol levels
in streptozotocin induced diabetes model
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Effect of Coldenia procumbens extracts on triglyceride levels in streptozotocin
induced diabetes model
Rats in group I (normal control) showed triglyceride level of 83.10 ± 2.82,
87.90 ± 3.23 and 90.98 ± 3.88 at 0, 14 and 28 day of experiment respectively. In
group I, no change in triglyceride level is observed at 14 and 28 day of experiment.
Rats in group II, showed triglyceride level of 88.07 ± 7.11, 99.08 ± 5.01 and 145.00 ±
0.11 at 0, 14, and 28 day of experiment respectively. In group II, significant increase
in triglyceride level is observed at 14 and 28 day of experiment compared to normal
control. Rats in group III, showed triglyceride level of 84.67 ± 3.25, 79.80 ± 3.54 and
120.01 ± 3.91 at 0, 14 and 28 day of experiment respectively. In group III, significant
reduction in triglyceride level was observed at 14 and 28 day of experiment, when
compared to group II. Rats in group IV, showed triglyceride levels of 83.90 ± 4.51,
89.10 ± 2.76 and 114.30 ± 3.14 at 0, 14 and 28 day of experiment respectively. In
group IV, significant reduction in triglyceride level was observed at 14 and 28 day of
experiment compared to group II. Based on these results, it is evident that extracts at
250 mg/kg of body weight showed reduction in triglyceride levels. Results are given
in Table 12 and Figure 17.
Table 12: Effect of Coldenia procumbens extracts on triglyceride levels in
streptozotocin induced diabetes model.
Experimental Groups
Triglyceride levels (Mean ± S.E.) (mg/dl)
Day 0 Day 14 Day 28
Group I-
Normal control
83.10 ± 2.82 87.90 ± 3.23 90.98 ± 3.88
Group II-
STZ  control
88.07 ± 7.11 99.08 ± 5.01a 145.00 ± 0.11a
Group III-
90% ethanol extract
(250 mg/kg)
84.67 ± 3.25 79.80 ± 3.54b 120.01 ± 3.91b
Group IV-
50%   ethanol
extract (250 mg/kg)
83.90 ± 4.51 89.10 ± 2.76b 114.30 ± 3.14b
Results were expressed as Mean ± S.E.M.  a’ = p<0.05 compared to Normal control
‘b’= p<0.05 compared to STZ control group.
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Fig 17. Effect of Coldenia procumbens extracts on triglyceride levels in
streptozotocin induced diabetes model
Results were expressed as Mean ± S.E.M.  ‘a’ = p<0.05 compared to Normal control
‘b’= p<0.05 compared to STZ control group.
People with diabetes tend to have high levels of triglycerides and LDL
cholesterol, combined with low levels of HDL, the "good" cholesterol, a condition
known as diabetic dyslipidemia. The greatest link between diabetes and triglycerides
was found. It showed that diabetics with high triglyceride levels were much more
likely to develop nerve damage, or neuropathy. People suffering from diabetic
neuropathy experience a painful tingling and numbing in their extremities as nerves
are damaged or lost. High triglyceride levels that accompany either normal or
impaired fasting glucose predict the development of type 2 diabetes and therefore,
hypertriglyceridemic states should prompt surveillance to rule out type 2 diabetes88.
200 mg/dL168 associated with decreased HDL-C and small, dense LDL
particles89. Hence, reduction in the triglyceride is necessary to avoid future event of
cardiovascular diseases/complications. However, the extracts used showed significant
reduction in the levels of triglycerides in the animals further confirms the antidiabetic
activity.
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6. SUMMARY AND CONCLUSION
The present study was designed to evaluate the antidiabetic potential of
Coldenia procumbens. Preliminary chemical studies included qualitative chemical
tests. Antidiabetic evaluation of Coldenia procumbens was done using 18 hr fasting
glucose model, oral glucose tolerance test and streptozotocin induced diabetes model.
Qualitative chemical tests revealed the presence of carbohydrates, flavonoids,
steroids, tannins and phenolic compounds in 50% ethanol extract and 90% ethanol
extract and presence of carbohydrates, proteins and amino acids, flavonoids, steroids,
tannins and phenolic compounds in aqueous extract.
Antidiabetic studies on 50% ethanol extract, 90% ethanol extract and aqueous
extract of Coldenia procumbens was carried out using fasting glucose model, oral
glucose tolerance test and streptozotocin induced diabetes model. 90% ethanol
extract, 50% ethanol extract and aqueous extracts in dose of 250 mg/kg were devoid
of  hypoglycemic activity in fasting glucose model. 90% ethanol extract and 50%
ethanol extract in the dose of 250 mg/kg showed antihyperglycaemic activity in oral
glucose tolerance test. 50% ethanol extract is more effective than 90% ethanol extract
in oral glucose tolerance test. 90% Ethanol extract and 50% Ethanol extract in dose of
250mg/kg showed antidiabetic activity in streptozotocin induced diabetic rats. 50%
ethanol extract is more effective than 90% ethanol extract in the dose of 250 mg/kg in
streptozotocin induced diabetic rats. 50% ethanol extract of Coldenia procumbens
showed significant reduction in triglycerides levels in streptozotocin induced diabetic
rats.
Effect on blood glucose level in  fasting glucose model: In the single dose treatment
at 250mg/kg p.o., none of the three extracts of Coldenia procumbens showed
hypoglycemic activity in fasting glucose model which indicates that these extracts
were devoid of insulin secreting or insulin like activity.
Effect on blood glucose level in oral glucose tolerance test: In oral glucose
tolerance test (OGTT) the lowering of blood glucose was observed at 30 and 60min.
post glucose administration when compared to control.
Effect on blood glucose level in streptozotocin induced diabetes model: In
streptozotocin induced diabetes model, both the extracts i.e. 50% ethanol extract and
90% ethanol extract of Coldenia procumbens exhibited varied degree of reversal of
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diabetic condition with maximum effect in 50% ethanol extract when compared to the
streptozotocin control. In the group treated with 50% ethanol extract, the blood
glucose level significantly reduced to 146.85 ± 14.18 mg/dl on day 28 as compared to
that of 300.10 ± 23.03 mg/dl in streptozotocin control.
The 50% ethanol extract may be subjected fractionation in order to enrich an
active fraction and thereby the phytochemical responsible for this antidiabetic activity
may be identified, isolated and characterized. It may be concluded that the leaves of
Coldenia procumbens possess antidabetic activity in animal models.
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